Do analysts recommend TUYA or DMAA?

Tuya presently has a consensus price target of $3.69, suggesting a potential upside of 102.19%. Given Tuya's stronger consensus rating and higher probable upside, analysts plainly believe Tuya is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tuya 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, TUYA or DMAA?

Tuya has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tuya $321.79M 3.08 $57.89M $0.10 18.25 Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Does the media favor TUYA or DMAA?

In the previous week, Drugs Made In America Acquisition had 1 more articles in the media than Tuya. MarketBeat recorded 2 mentions for Drugs Made In America Acquisition and 1 mentions for Tuya. Drugs Made In America Acquisition's average media sentiment score of 0.93 beat Tuya's score of 0.00 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tuya 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Drugs Made In America Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DMAA or RZLV?

Rezolve AI has a consensus target price of $11.42, suggesting a potential upside of 327.59%. Given Rezolve AI's stronger consensus rating and higher probable upside, analysts clearly believe Rezolve AI is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rezolve AI 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable earnings & valuation, DMAA or RZLV?

Drugs Made In America Acquisition has higher earnings, but lower revenue than Rezolve AI. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A Rezolve AI $48.80M 18.40 -$101.41M N/A N/A

Is DMAA or RZLV more profitable?

Company Net Margins Return on Equity Return on Assets Drugs Made In America Acquisition N/A N/A N/A Rezolve AI N/A N/A N/A

Does the media refer more to DMAA or RZLV?

In the previous week, Rezolve AI had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 4 mentions for Rezolve AI and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.93 beat Rezolve AI's score of 0.61 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Drugs Made In America Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolve AI 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DMAA or PD?

PagerDuty has a consensus target price of $11.88, indicating a potential downside of 0.08%. Given PagerDuty's stronger consensus rating and higher possible upside, analysts clearly believe PagerDuty is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PagerDuty 3 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, DMAA or PD?

PagerDuty has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A PagerDuty $492.55M 1.86 $173.85M $2.04 5.83

Does the media refer more to DMAA or PD?

In the previous week, PagerDuty had 4 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 6 mentions for PagerDuty and 2 mentions for Drugs Made In America Acquisition. PagerDuty's average media sentiment score of 1.16 beat Drugs Made In America Acquisition's score of 0.93 indicating that PagerDuty is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Drugs Made In America Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PagerDuty 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend DMAA or DSP?

Viant Technology has a consensus target price of $18.33, indicating a potential upside of 40.92%. Given Viant Technology's stronger consensus rating and higher probable upside, analysts plainly believe Viant Technology is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Viant Technology 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has better earnings & valuation, DMAA or DSP?

Viant Technology has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A Viant Technology $344.20M 2.51 $8.35M $0.31 41.97

Do analysts prefer MGIC or DMAA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Magic Software Enterprises 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, MGIC or DMAA?

Magic Software Enterprises has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Magic Software Enterprises $603.22M 1.41 $36.88M $0.81 21.46 Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Drugs Made In America Acquisition (DMAA) Competitors

$10.71 0.00 (-0.01%)

Closing price 08/14/2026 10:42 AM Eastern

Extended Trading

$10.71 +0.00 (+0.01%)

As of 08/14/2026 04:04 PM Eastern

Compare

DMAA vs. TUYA, RZLV, PD, DSP, and MGIC

Should you buy Drugs Made In America Acquisition stock or one of its competitors? Drugs Made In America Acquisition's main competitors and comparable companies include Tuya (TUYA), Rezolve AI (RZLV), PagerDuty (PD), Viant Technology (DSP), and Magic Software Enterprises (MGIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Drugs Made In America Acquisition compare to Tuya?

Tuya (NYSE:TUYA) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Tuya has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tuya	$321.79M	3.08	$57.89M	$0.10	18.25
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Tuya has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Tuya presently has a consensus price target of $3.69, suggesting a potential upside of 102.19%. Given Tuya's stronger consensus rating and higher probable upside, analysts plainly believe Tuya is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tuya	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tuya has a net margin of 19.10% compared to Drugs Made In America Acquisition's net margin of 0.00%. Tuya's return on equity of 6.20% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tuya	19.10%	6.20%	5.53%
Drugs Made In America Acquisition	N/A	N/A	N/A

In the previous week, Drugs Made In America Acquisition had 1 more articles in the media than Tuya. MarketBeat recorded 2 mentions for Drugs Made In America Acquisition and 1 mentions for Tuya. Drugs Made In America Acquisition's average media sentiment score of 0.93 beat Tuya's score of 0.00 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tuya	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Drugs Made In America Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.5% of Tuya shares are owned by institutional investors. 2.1% of Tuya shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tuya beats Drugs Made In America Acquisition on 10 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Rezolve AI?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Rezolve AI (NASDAQ:RZLV) are both small-cap technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Rezolve AI has a consensus target price of $11.42, suggesting a potential upside of 327.59%. Given Rezolve AI's stronger consensus rating and higher probable upside, analysts clearly believe Rezolve AI is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rezolve AI	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

28.0% of Rezolve AI shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 68.7% of Rezolve AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Rezolve AI had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 4 mentions for Rezolve AI and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.93 beat Rezolve AI's score of 0.61 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolve AI	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Rezolve AI	N/A	N/A	N/A

Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Rezolve AI has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Drugs Made In America Acquisition has higher earnings, but lower revenue than Rezolve AI.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Rezolve AI	$48.80M	18.40	-$101.41M	N/A	N/A

Summary

Rezolve AI beats Drugs Made In America Acquisition on 7 of the 9 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to PagerDuty?

Drugs Made In America Acquisition (NASDAQ:DMAA) and PagerDuty (NYSE:PD) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

97.3% of PagerDuty shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Comparatively, 6.0% of PagerDuty shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PagerDuty has a net margin of 38.60% compared to Drugs Made In America Acquisition's net margin of 0.00%. PagerDuty's return on equity of 18.20% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
PagerDuty	38.60%	18.20%	4.60%

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, PagerDuty has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

PagerDuty has a consensus target price of $11.88, indicating a potential downside of 0.08%. Given PagerDuty's stronger consensus rating and higher possible upside, analysts clearly believe PagerDuty is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PagerDuty	3 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

PagerDuty has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
PagerDuty	$492.55M	1.86	$173.85M	$2.04	5.83

In the previous week, PagerDuty had 4 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 6 mentions for PagerDuty and 2 mentions for Drugs Made In America Acquisition. PagerDuty's average media sentiment score of 1.16 beat Drugs Made In America Acquisition's score of 0.93 indicating that PagerDuty is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PagerDuty	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PagerDuty beats Drugs Made In America Acquisition on 12 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Viant Technology?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Viant Technology (NASDAQ:DSP) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Viant Technology had 27 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 29 mentions for Viant Technology and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.93 beat Viant Technology's score of 0.56 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viant Technology	6 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viant Technology has a consensus target price of $18.33, indicating a potential upside of 40.92%. Given Viant Technology's stronger consensus rating and higher probable upside, analysts plainly believe Viant Technology is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Viant Technology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Drugs Made In America Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Viant Technology has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

11.4% of Viant Technology shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Comparatively, 29.4% of Viant Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viant Technology has a net margin of 2.24% compared to Drugs Made In America Acquisition's net margin of 0.00%. Viant Technology's return on equity of 4.23% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Viant Technology	2.24%	4.23%	2.71%

Viant Technology has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Viant Technology	$344.20M	2.51	$8.35M	$0.31	41.97

Summary

Viant Technology beats Drugs Made In America Acquisition on 12 of the 13 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Magic Software Enterprises (NASDAQ:MGIC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Magic Software Enterprises has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

24.7% of Magic Software Enterprises shares are owned by institutional investors. 4.5% of Magic Software Enterprises shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Magic Software Enterprises has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Magic Software Enterprises	$603.22M	1.41	$36.88M	$0.81	21.46
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Drugs Made In America Acquisition had 2 more articles in the media than Magic Software Enterprises. MarketBeat recorded 2 mentions for Drugs Made In America Acquisition and 0 mentions for Magic Software Enterprises. Drugs Made In America Acquisition's average media sentiment score of 0.93 beat Magic Software Enterprises' score of 0.00 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Magic Software Enterprises	Neutral
Drugs Made In America Acquisition	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Magic Software Enterprises	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Magic Software Enterprises has a net margin of 6.61% compared to Drugs Made In America Acquisition's net margin of 0.00%. Magic Software Enterprises' return on equity of 16.28% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Magic Software Enterprises	6.61%	16.28%	8.96%
Drugs Made In America Acquisition	N/A	N/A	N/A

Summary

Magic Software Enterprises beats Drugs Made In America Acquisition on 8 of the 10 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAA vs. The Competition

Export

Metric	Drugs Made In America Acquisition	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$260.01M	$15.99B	$30.69B	$13.10B
Dividend Yield	N/A	3.43%	2.73%	10.45%
P/E Ratio	N/A	127.92	75.53	25.28
Price / Sales	N/A	1,304.97	602.17	91.83
Price / Cash	N/A	48.98	53.72	50.90
Price / Book	N/A	7.34	9.57	6.24
Net Income	N/A	$436.26M	$681.19M	$347.60M
7 Day Performance	0.04%	0.15%	1.42%	1.06%
1 Month Performance	0.27%	2.62%	2.75%	0.81%
1 Year Performance	4.27%	7.15%	199.68%	20.90%

Drugs Made In America Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAA Drugs Made In America Acquisition	1.2052 of 5 stars	$10.71 0.0%	N/A	+4.2%	$260.01M	N/A	N/A	2
TUYA Tuya	3.6187 of 5 stars	$1.80 +2.0%	$3.69 +105.6%	-24.4%	$977.77M	$321.79M	17.95	1,441	Dividend Announcement
RZLV Rezolve AI	2.1982 of 5 stars	$2.73 +3.4%	$11.42 +318.2%	-13.0%	$918.18M	$48.80M	N/A	N/A
PD PagerDuty	2.0292 of 5 stars	$11.68 +5.2%	$11.50 -1.5%	-23.1%	$901.57M	$492.55M	5.73	1,155	Positive News Analyst Forecast Gap Up
DSP Viant Technology	4.0245 of 5 stars	$13.24 +7.5%	$18.00 +36.0%	+36.5%	$867.67M	$344.20M	36.78	350	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. TUYA, RZLV, PD, DSP, and MGIC

How does Drugs Made In America Acquisition compare to Tuya?

Summary

How does Drugs Made In America Acquisition compare to Rezolve AI?

Summary

How does Drugs Made In America Acquisition compare to PagerDuty?

Summary

How does Drugs Made In America Acquisition compare to Viant Technology?

Summary

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. TUYA, RZLV, PD, DSP, and MGIC

How does Drugs Made In America Acquisition compare to Tuya?

Which has preferable earnings & valuation, TUYA or DMAA?

Which has more volatility & risk, TUYA or DMAA?

Do analysts recommend TUYA or DMAA?

Is TUYA or DMAA more profitable?

Does the media favor TUYA or DMAA?

Do institutionals and insiders hold more shares of TUYA or DMAA?

Summary

How does Drugs Made In America Acquisition compare to Rezolve AI?

Do analysts prefer DMAA or RZLV?

Do institutionals and insiders hold more shares of DMAA or RZLV?

Does the media refer more to DMAA or RZLV?

Is DMAA or RZLV more profitable?

Which has more risk and volatility, DMAA or RZLV?

Which has preferable earnings & valuation, DMAA or RZLV?

Summary

How does Drugs Made In America Acquisition compare to PagerDuty?

Do institutionals & insiders have more ownership in DMAA or PD?

Is DMAA or PD more profitable?

Which has more volatility and risk, DMAA or PD?

Do analysts prefer DMAA or PD?

Which has better valuation & earnings, DMAA or PD?

Does the media refer more to DMAA or PD?

Summary

How does Drugs Made In America Acquisition compare to Viant Technology?

Does the media favor DMAA or DSP?

Do analysts recommend DMAA or DSP?

Which has more risk and volatility, DMAA or DSP?

Do institutionals & insiders believe in DMAA or DSP?

Is DMAA or DSP more profitable?

Which has better earnings & valuation, DMAA or DSP?

Summary

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Which has more risk & volatility, MGIC or DMAA?

Do institutionals and insiders hold more shares of MGIC or DMAA?

Which has preferable valuation & earnings, MGIC or DMAA?

Does the media refer more to MGIC or DMAA?

Do analysts prefer MGIC or DMAA?

Is MGIC or DMAA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools